Tearsheet
Investment Highlights Market Valuation Price Chart Return vs. Risk About EXAS Interactive Breakdown Better Bets vs. EXAS Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Exact Sciences (EXAS)

Market Price (10/26/2025): $64.64 | Market Cap: $12.2 Bil
Sector: Health Care | Industry: Life Sciences Tools & Services

Exact Sciences (EXAS)

Market Price (10/26/2025): $64.64
Market Cap: $12.2 Bil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 10%		 Weak multi-year price returns
2Y Excs Rtn is -60%		 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -151 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -5.1%
1 Low stock price volatility
Vol 12M is 49%		  Expensive valuation multiples
P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 40x
2   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -13%
0 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 10%
1 Low stock price volatility
Vol 12M is 49%
2 Weak multi-year price returns
2Y Excs Rtn is -60%
3 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -151 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -5.1%
4 Expensive valuation multiples
P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 40x
5 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -13%

Market Valuation & Key Metrics

EXASS&P 500
REVENUE GROWTHGOOD
Rev LTM ($ Bil)2.9
Rev Chg Q16.0%6.4%
Rev Chg LTM12.6%5.3%
Rev Chg 3Y Avg14.9%5.4%
PROFITABILITYVERY POOR
Op Inc LTM ($ Bil)-0.2
CFO LTM ($ Bil)0.3
Net Inc LTM ($ Bil)-1.0
Op Mgn LTM-5.1%18.7%
CFO/Rev LTM10.4%20.4%
Net Inc Mgn-34.2%12.7%
VALUATIONVERY HIGH
P/S4.23.3
P/CFO40.016.1
P/FCF72.020.9
P/E-12.124.0
STABILITYVERY GOOD
Debt/Equity0.210.21
Cash/Assets0.150.07

EXAS Stock

   
   
   
   
   
   
   

Return vs. Risk

Price Returns Compared

 202020212022202320242025Total [1]
Returns
EXAS Return43%-41%-36%49%-24%15%-30%
Peers Return30%2%-47%-19%-19%-32%-69%
S&P 500 Return16%27%-19%24%23%15%110%

Monthly Win Rates [3]
EXAS Win Rate67%25%42%58%42%44% 
Peers Win Rate27%38%33%33%37%40% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
EXAS Max Drawdown-59%-45%-61%-5%-44%-28% 
Peers Max Drawdown-9%-14%-58%-42%-38%-52% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 

[1] Cumulative total returns since the beginning of 2020
[2] Peers: TNDM, SKIN, CTSO, NMTC, BDMD. See EXAS Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/24/2025 (YTD)

How Low Can It Go

Unique KeyEventEXASS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-80.4%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven410.7%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-63.7%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven175.6%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven197 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-37.5%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven59.9%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven59 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-94.2%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven1620.0%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven661 days1480 days

Compare to TNDM, SKIN, CTSO, NMTC, BDMD


In The Past

Exact Sciences's stock fell -80.4% during the 2022 Inflation Shock from a high on 2/12/2021. A -80.4% loss requires a 410.7% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Exact Sciences (EXAS)

Better Bets than Exact Sciences (EXAS)

 EXASBetter Performance than EXAS
MetricValueIndustry (Life Sciences Tools & Services)
Rev Chg LTM12.6%NTRA (44.4%), MEDP (13.9%), GH (28.2%), IRTC (22.4%), WGS (48.7%)
Rev Chg 3Y Avg14.9%NTRA (39.7%), MEDP (19.9%), GH (25.6%), IRTC (22.1%), WGS (25.2%)
Op Mgn LTM-5.1%TMO (18.2%), DHR (19.0%), A (21.3%), IQV (14.4%), MTD (28.4%)
CFO/Rev LTM10.4%TMO (17.5%), DHR (26.0%), A (22.0%), IQV (16.7%), MTD (24.6%)
FCF/Rev LTM5.8%TMO (14.3%), DHR (20.7%), A (16.0%), IQV (12.8%), MTD (21.9%)
Total Yield-8.2%TMO (3.0%), DHR (2.2%), A (3.6%), IQV (3.3%), MTD (2.8%)
 EXASBetter Performance than EXAS
MetricValueAll Other Sectors
Rev Chg LTM12.6%NVDA (71.6%), MSFT (14.9%), GOOGL (13.1%), META (19.4%), AVGO (28.0%)
Rev Chg 3Y Avg14.9%NVDA (92.0%), AVGO (24.0%), PLTR (25.7%), GE (15.7%), TM (15.2%)
Op Mgn LTM-5.1%NVDA (58.1%), AAPL (31.9%), MSFT (45.6%), GOOGL (32.7%), AMZN (11.4%)
CFO/Rev LTM10.4%NVDA (46.6%), AAPL (26.6%), MSFT (48.3%), GOOGL (36.0%), AMZN (18.1%)
FCF/Rev LTM5.8%NVDA (43.6%), AAPL (23.5%), MSFT (25.4%), GOOGL (18.0%), META (30.7%)
Total Yield-8.2%NVDA (1.9%), AAPL (2.9%), MSFT (3.2%), GOOGL (4.0%), AMZN (3.0%)
 Best Bets In Health Care Sector
 EXASRPRX HALO CPRX LNTH PBH EW AVTR ILMN HCA THC
What You Pay           
P/E-12.115.514.412.314.214.510.815.312.517.912.9
P/EBIT-12.38.211.310.59.79.326.610.410.49.85.0
What You Get           
Rev Chg Q16.0%7.7%40.8%19.4%-4.1%-6.6%11.9%-1.1%-4.8%6.4%3.2%
Rev Chg LTM12.6%3.0%35.0%28.5%5.7%0.6%9.1%-2.3%-3.3%6.4%-1.1%
Rev Chg 3Y Avg14.9%0.8%35.5%49.9%34.3%0.8%3.0%-4.3%-3.0%6.6%2.7%
FCF/Rev 3Y Avg0.2%113.4%43.4%38.9%26.1%21.6%11.9%9.7%9.0%8.4%7.1%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Exact Sciences Earnings Notes  
2With Exact Sciences Stock Climbed 20% In A Month, How Confident Are You?Return 
3How Does Exact Sciences Stock Compare With Peers?Peer Comparison 
4Is The 25.9% Decline In Exact Sciences (EXAS) Stock A Dip Buying Opportunity?Actionable 
5EXAS Dip Buy Analysis  
6Exact Sciences (EXAS) Operating Cash Flow ComparisonFinancials 
7Exact Sciences (EXAS) Net Income ComparisonFinancials 
8Exact Sciences (EXAS) Operating Income ComparisonFinancials 
9Exact Sciences (EXAS) Revenue ComparisonFinancials 
10Day 0 of Loss Streak for Exact Sciences Stock with 0% Return (vs. -16% YTD) [12/2/2024]Notification 
11ARTICLES  
12EXAS Shares Tumbled 26%, Opportunity Or Trap? August 9th, 2025
13EXAS Looks Stronger Than TMO With 50% Return Potential July 31st, 2025
14Strong Revenue Trend Could Drive EXACT Sciences Corporation Stock To $160 June 17th, 2021

Trade Ideas

Select past ideas related to EXAS. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		3.5%3.5%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		2.8%2.8%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		6.4%6.4%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		19.5%19.5%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		17.1%17.1%-8.0%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		3.5%3.5%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		2.8%2.8%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		6.4%6.4%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		19.5%19.5%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		17.1%17.1%-8.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1VICRVicor57.5%87.2%
2INBXInhibrx Biosciences53.8%272.0%
3CLBCore Laboratories48.7%-2.4%
4BALYBallys46.2%6.8%
5MOFGMidWestOne Financial43.2%39.2%
6NUVBNuvation Bio42.2%82.3%
7CLOVClover Health Investments41.0%21.3%
8CELCCelcuity36.6%442.2%
9WGOWinnebago Industries33.6%-12.7%
10GTXGarrett Motion33.3%91.3%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-45.4%8328.6%
2ITGRInteger-30.4%-45.0%
3METCRamaco Resources-23.8%244.9%
4WRLDWorld Acceptance-18.6%25.6%
5ASMAvino Silver & Gold Mines-18.2%450.5%
6SESSES AI-17.6%15.5%
7SMPLSimply Good Foods-17.5%-48.0%
8TNGXTango Therapeutics-17.0%142.6%
9OKLOOklo-16.7%540.8%
10LENZLENZ Therapeutics-16.4%10.7%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1WOLFWolfspeed1498.4%344.0%
2PRAXPraxis Precision Medicines253.2%126.1%
3NVTSNavitas Semiconductor116.1%294.1%
4SNDKSanDisk97.4% 
5UAMYUnited States Antimony90.3%578.5%
6GRALGRAIL85.2%400.8%
7BALYBallys82.9%6.8%
8ORKAOruka Therapeutics81.1%40.5%
9INBXInhibrx Biosciences79.9%272.0%
10CIFRCipher Mining77.2%345.3%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1VGVenture Global-35.7% 
2PMIPicard Medical-35.3%8328.6%
3SOCSable Offshore-33.7%-41.7%
4FWRDForward Air-28.9%-39.0%
5FLYFirefly Aerospace-28.5% 
6ITGRInteger-28.4%-45.0%
7USNAUsana Health Sciences-26.5%-42.0%
8HTZHertz Global-26.3%41.5%
9RCReady Capital-25.1%-50.3%
10ULHUniversal Logistics-24.8%-61.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1VICRVicor57.5%87.2%
2INBXInhibrx Biosciences53.8%272.0%
3CLBCore Laboratories48.7%-2.4%
4BALYBallys46.2%6.8%
5MOFGMidWestOne Financial43.2%39.2%
6NUVBNuvation Bio42.2%82.3%
7CLOVClover Health Investments41.0%21.3%
8CELCCelcuity36.6%442.2%
9WGOWinnebago Industries33.6%-12.7%
10GTXGarrett Motion33.3%91.3%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-45.4%8328.6%
2ITGRInteger-30.4%-45.0%
3METCRamaco Resources-23.8%244.9%
4WRLDWorld Acceptance-18.6%25.6%
5ASMAvino Silver & Gold Mines-18.2%450.5%
6SESSES AI-17.6%15.5%
7SMPLSimply Good Foods-17.5%-48.0%
8TNGXTango Therapeutics-17.0%142.6%
9OKLOOklo-16.7%540.8%
10LENZLENZ Therapeutics-16.4%10.7%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Exact Sciences

Financials

EXASTNDMSKINCTSONMTCBDMDMedian
NameExact Sc.Tandem D.Beauty H.CytoSorb.NeuroOne.Baird Me. 
Mkt Price64.6414.951.390.850.821.401.40
Mkt Cap12.21.00.20.10.0-0.2
Rev LTM2,9401,002310367-310
Op Inc LTM-151-179-43-16-6--43
FCF LTM170-5134-10-4--4
FCF 3Y Avg15-44-6-19-8--8
CFO LTM3061039-10-4-10
CFO 3Y Avg166-25-18-8--2

Growth & Margins

EXASTNDMSKINCTSONMTCBDMDMedian
NameExact Sc.Tandem D.Beauty H.CytoSorb.NeuroOne.Baird Me. 
Rev Chg LTM12.6%25.8%-15.3%9.6%69.0%-12.6%
Rev Chg 3Y Avg14.9%9.9%-0.5%2.7%341.5%-9.9%
Rev Chg Q16.0%8.5%-13.7%8.8%105.4%-8.8%
QoQ Delta Rev Chg LTM4.0%1.9%-3.8%2.2%15.1%-2.2%
Op Mgn LTM-5.1%-17.9%-14.0%-44.2%-85.6%--17.9%
Op Mgn 3Y Avg-9.8%-24.9%-20.5%-73.7%-398.0%--24.9%
QoQ Delta Op Mgn LTM0.8%0.2%5.5%0.8%28.7%-0.8%
CFO/Rev LTM10.4%1.0%12.7%-27.1%-60.0%-1.0%
CFO/Rev 3Y Avg6.0%-0.3%2.1%-55.0%-349.2%--0.3%
FCF/Rev LTM5.8%-5.1%10.9%-28.8%-61.6%--5.1%
FCF/Rev 3Y Avg0.2%-5.1%-0.9%-58.0%-361.2%--5.1%

Valuation

EXASTNDMSKINCTSONMTCBDMDMedian
NameExact Sc.Tandem D.Beauty H.CytoSorb.NeuroOne.Baird Me. 
Mkt Cap12.21.00.20.10.0-0.2
P/S4.21.00.61.56.0-1.5
P/EBIT-12.3-5.1-25.1-5.9-8.3--8.3
P/E-12.1-4.9-9.2-5.5-7.5--7.5
P/CFO40.0103.14.4-5.4-10.0-4.4
Total Yield-8.2%-20.5%-10.8%-18.3%-13.4%--13.4%
Dividend Yield0.0%0.0%0.0%0.0%0.0%-0.0%
FCF Yield 3Y Avg0.3%-2.7%2.3%-28.4%-36.3%--2.7%
D/E0.20.42.10.50.0-0.4
Net D/E0.10.10.90.3-0.2-0.1

Returns

EXASTNDMSKINCTSONMTCBDMDMedian
NameExact Sc.Tandem D.Beauty H.CytoSorb.NeuroOne.Baird Me. 
1M Rtn20.4%25.0%-28.4%-8.2%-9.3%-39.9%-8.7%
3M Rtn33.3%-5.9%-22.3%-9.9%-8.0%-31.4%-9.0%
6M Rtn42.2%-17.2%40.4%-22.7%25.1%-75.5%3.9%
12M Rtn-6.5%-52.3%-15.8%-18.3%-13.3%-54.5%-17.0%
3Y Rtn84.3%-73.2%-88.7%-53.5%-42.2%--53.5%
1M Excs Rtn17.6%22.2%-31.2%-11.0%-12.1%-42.7%-11.6%
3M Excs Rtn28.3%-17.5%-27.3%-16.0%-10.6%-39.6%-16.8%
6M Excs Rtn19.3%-40.1%17.4%-45.6%2.2%-98.4%-19.0%
12M Excs Rtn-24.5%-71.5%-32.8%-34.3%-27.4%-73.0%-33.6%
3Y Excs Rtn13.9%-155.1%-171.8%-131.0%-128.3%--131.0%

Comparison Analyses

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/2022
Filing Date8/6/20255/1/20252/19/202511/5/20247/31/20245/8/20242/21/202411/1/20238/1/20235/9/20232/21/202311/3/2022
Key Financials Quarterly            
Total Revenue811707713709699638647628622602553523
Ebitda53-38-8152635-481060-26-27-76-100
Operating Income-2-90-38-21-18-102-687-76-77-115-132
Net Income-1-101-865-38-16-110-501-81-74-128-149
EPS-0.01-0.54-4.67-0.21-0.09-0.60-0.270.00-0.45-0.42-0.72-0.84
Key Financials TTM            
Total Revenue TTM2,9402,8282,7592,6922,6122,5352,5002,4062,3012,2002,0842,005
Ebitda TTM-774-792-8022357-417-70-229-315-418-518
Operating Income TTM-151-167-179-209-181-240-214-262-401-478-578-684
Net Income TTM-1,005-1,020-1,029-214-175-240-204-282-432-517-624-716
Growth Rates Quarterly            
Total Revenue Growth16.0%10.9%10.3%12.8%12.4%5.8%17.0%20.1%19.3%23.8%16.7%14.6%
EBITDA Growth52.3%20.4%-7984.0%-57.2%234.2%-74.9%113.5%160.1%76.7%79.1%56.7%18.0%
Operating Income Growth88.1%12.2%43.8%-404.4%76.3%-32.6%41.3%105.2%50.0%56.5%47.9%6.8%
Net Income Growth92.5%8.2%-1637.3%-4915.6%80.5%-48.7%61.0%100.5%51.2%59.0%42.1%10.9%
Margins Quarterly            
EBITDA Margin6.6%-5.4%-114.2%3.6%5.0%-7.5%1.6%9.5%-4.2%-4.5%-13.8%-19.0%
Operating Income Margin-0.3%-12.7%-5.3%-2.9%-2.6%-16.0%-10.5%1.1%-12.3%-12.8%-20.9%-25.3%
Net Income Margin-0.1%-14.3%-121.2%-5.4%-2.3%-17.3%-7.7%0.1%-13.0%-12.3%-23.1%-28.4%
Cash & Debt            
Total Cash8587861,0381,021947652778734776699632669
Total Debt2,5212,5212,7552,7582,7622,5552,5552,5622,5602,5652,4472,446
Net Debt / (Cash)1,6631,7351,7171,7371,8151,9031,7771,8271,7841,8661,8151,777
Cash Flows Quarterly            
FCF from Operations893147139107-827024100-3852-41
Cash Flows TTM            
FCF from Operations TTM30632421123311911215613973-88-224-300
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC-0.1%-4.1%-1.7%-1.0%-0.8%-4.7%-3.2%0.2%-3.7%-3.7%-5.6%-6.5%
Return on Invested Capital (ROIC) TTM            
ROIC TTM-1.7%-1.9%-2.1%-2.4%-2.1%-2.8%-2.6%-3.1%-4.8%-5.7%-7.0%-8.4%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Development and global commercialization of clinical laboratory services2,5002,084   
COVID-19 Testing  143236 
Commercial  750596398
International  1107711
Medicare parts B & C  636523429
Other  1286038
Total2,5002,0841,7671,491876


Net Income by Segment
$ Mil20242023202220212020
Development and global commercialization of clinical laboratory services-204-624   
Total-204-624   


Price Behavior

EXAS Betas & Captures as of 9/30/2025

 1M2M3M6M1Y3Y
Beta1.190.160.260.850.761.09
Up Beta4.17-0.66-0.751.120.801.15
Down Beta-3.66-2.65-1.680.440.570.89
Up Capture248%160%97%89%54%136%
Bmk +ve Days13233574144420
Stock +ve Days12253362116358
Down Capture-11%61%138%77%100%104%
Bmk -ve Days8192952107330
Stock -ve Days9173063134388

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date10152025
Short Interest: Shares Quantity7,968,887
Short Interest: % Change Since 930202518.7%
Average Daily Volume1,991,847
Days-to-Cover Short Interest4
Basic Shares Quantity188,902,000
Short % of Basic Shares4.2%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/6/2025-8.0%-4.3%14.7%
5/1/20259.3%12.5%19.0%
2/19/2025-1.9%-3.9%-12.3%
11/5/2024-23.5%-29.9%-12.4%
7/31/202426.8%22.6%36.3%
5/8/2024-9.0%-10.3%-27.8%
2/21/2024-6.0%-11.0%-2.0%
11/1/2023-1.7%-1.1%5.5%
...
SUMMARY STATS   
# Positive71010
# Negative161313
Median Positive10.9%12.2%13.0%
Median Negative-5.3%-10.2%-12.4%
Max Positive26.8%35.9%40.8%
Max Negative-23.5%-29.9%-27.8%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025806202510-Q 6/30/2025
3312025501202510-Q 3/31/2025
12312024219202510-K 12/31/2024
93020241105202410-Q 9/30/2024
6302024731202410-Q 6/30/2024
3312024508202410-Q 3/31/2024
12312023221202410-K 12/31/2023
93020231101202310-Q 9/30/2023
6302023801202310-Q 6/30/2023
3312023509202310-Q 3/31/2023
12312022221202310-K 12/31/2022
93020221103202210-Q 9/30/2022
6302022802202210-Q 6/30/2022
3312022426202210-Q 3/31/2022
12312021222202210-K 12/31/2021
93020211102202110-Q 9/30/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Doyle James Edward 8142025Sell42.021,48562,4002,519,603Form
1Conroy Kevin TPresident and CEO11132024Buy51.3519,5001,001,32555,159,708Form
2Baranick BrianEVP, GM, Precision Oncology10092024Sell70.0092965,030893,060Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.